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FOREWORD
This program was undertaken to evaluate possible interactions
among drugs contemplated for use during manned space flights. It was
carried out during the period July 1, 1972 to June 30, 1974 and was the
subject of our proposals dated March 10, 1972 and May 14, 1973, in
response to RFP No. 9-13B32-79-2-185P and RFP No. 9-13B631-4-3177P.
A Progress Report, dated October 31, 1973, was issued covering
the work completed during the period July 1972 to September 1973. This
final report includes the summary from the October 1973 report and the
details of the work from November 1973 to June 1974 when the program was
terminated.
Dr. Vernon Carter, formerly of the NASA Manned Spacecraft
Center, was the original Technical Officer for that agency. He has
recently been replaced by Dr. Harold Kaplan. Dr. David W. Yesair,
Dr. Francis J. Bullock (former Arthur D. Little, Inc. staff member),
Dr. Philip S. Thayer, Ms. Marianne Callahan, and Mr. James Braun comprised
the Arthur D. Little, Inc. project team.
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PART I: SUMMARY FROM PROGRESS REPORT FOR THE PERIOD JULY 1972 TO
SEPTEMBER 1973.
Possible interactions among drugs contemplated for use during
manned spaceflights have been studied in several animal species. The
following seven drugs were investigated: nitrofurantoin, chloral hydrate,
hexobarbital, phenobarbital, flurazepam, diphenoxylate, and phenazopyridine.
Particular combinations included: chloral hydrate, hexobarbital or
flurazepam with nitrofurantoin; phenobarbital or flurazepam with phenazo-
pyridine; and diphenoxylate with two dose formulations of nitrofurantoin.
Specifically, rat liver microsomes were used to determine whether
chronic dosage with nitrofurantoin would inhibit rates of oxidative
drug metabolism. Rates of hexobarbital oxidation, N-demethylation of
meperidine, and reduction of p-nitrobenzoic acid were studied in control
and nitrofurantoin-treated rats.
Pharmacological studies were carried out to determine whether
premedication of rats with nitrofurantoin would result in potentiation
of activity of hexobarbital, chloral hydrate, or flurazepam. This was
determined for chloral hydrate and hexobarbital by studies of sleeping
times determined by loss of the righting reflex. Flurazepam was
investigated by use of the inclined screen test. No potentiation of
activity was found between control and nitrofurantoin-treated animals.
Studies were carried out in several species to determine whether
induction of liver microsomal enzymes would increase the tendency of
phenazopyridine to produce methemoglobin in vivo. Animals were pre-
medicated with phenobarbital, a known inducer of azoreductase, and in a
separate experiment with flurazepam, before administration of phenazo-
pyridine. Methemoglobin production was determined in each animal after
receiving phenazopyridine. No evidence was found for increased production
of methemoglobin in the rat, dog, or rabbit that could be attributed to
increased amounts of microsomal enzymes.
3
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The final group of experiments was conducted to determine
whether premedication of the dog with diphenoxylate would result in
altered bioavailability of Furadantin or Macrodantin . The rate of
drug excretion in the urine was determined and a plot of percent drug
absorbed versus time was constructed for each dosage form, with and
without diphenoxylate pretreatment. Drug in the urine was determined
by both chemical and microbiological methods. Two doses of diphenoxylate
were studied in four female beagles with each dog serving as its own
pre-diphenoxylate control. Diphenoxylate was found to alter substantially
the excretion pattern of both forms of nitrofurantoin, generally
increasing total absorption.
On the basis of this work, the present contract was extended
to include nitrofurantoin/diphenoxylate studies in man. The clinical
study was carried out by Medical and Technical Research Associates, Inc.,
Needham, Massachusetts. Six subjects received both dosage forms of
nitrofurantoin alone, and in combination with diphenoxylate. The results
of these studies are inconclusive. The mechanism of action and an
explanation of the interaction between diphenoxylate and nitrofurantoin
still remains unclear. In man, the interaction does not appear to be
significant, affecting only two subjects out of six and with only one
formulation (Furadantin .
Arthur D Little, Inc
PART II: PROGRESS REPORT FOR THE PERIOD OCTOBER 1973 TO JUNE 1974.
SUMMARY
An extensive investigation has been carried out looking into
the pharmacodynamics of diphenoxylate interaction with certain drugs;
specifically, pentobarbital, phenobarbital, secobarbital, hexobarbital,
chloral hydrate, flurazepam, and meperidine. The various barbiturates
were chosen because they differ widely in their rates of absorption,
metabolism, and excretion, and in their duration of pharmacological
activity. Flurazepam was included because it, along with chloral
hydrate and secobarbital, is carried in the Sky Lab medical kit.
Meperidine was investigated for it appeared that such a combination
might yield additional information concerning the interaction between
diphenoxylate and CNS depressant drugs.
Pharmacological studies were carried out to determine whether
premedication of rats with diphenoxylate would result in potentiation
of activity with the second drug. Chloral hydrate, flurazepam, and the
barbiturates were investigated by measuring sleeping times in control
and diphenoxylate-treated rats. Pretreatment with diphenoxylate was
found to potentiate the activity of all the above-named sedative drugs.
When the concentration of the sedative drug was decreased, diphenoxylate
still increased the sedative-induced sleeping times. Diphenoxylate-
dosed rats given half the original dose of either of two barbiturates
or chloral hydrate, had sleeping times comparable to control animals
which received the full dose of the sedative.
Meperidine analgesia was measured by the Eddy hot plate
technique. Initial analgesic effect in diphenoxylate-pretreated rats
was greater than in control animals and, although the peak of analgesic
activity (measured at 20 min following meperidine injection) was the
same in both groups, the level of activity subsequently remained higher
in the diphenoxylate-pretreated rats.
More definitive pharmacological studies were carried out with
5
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secobarbital and chloral hydrate in an attempt to delineate the mechanism
of interaction between diphenoxylate and sedative drugs. Experiments
were conducted in which the concentration of diphenoxylate and its time
of administration, with respect to secobarbital and chloral hydrate, were
varied. As the dose of diphenoxylate was increased, the duration of
sleeping time with either drug also increased. With secobarbital, one
also saw an increase in sleeping times as the length of time between
dosing with diphenoxylate and dosing with secobarbital increased. With
chloral hydrate as the sedative drug, the only significant increase in
sleeping times occurred with the highest dose of diphenoxylate. Also,
as the time increased between dosing with diphenoxylate and dosing with
chloral hydrate at this high dose, the sleeping times, though still
significantly greater than in control rats, tended to decrease.
Physiological disposition studies were carried out to evaluate
the possibility that the pharmacological effect might relate closely to
the pharmacokinetics of the sedative drug in diphenoxylate-pretreated
rats. Radioactive sedative drugs were administered intravenously to
both normal and diphenoxylate-pretreated rats. Drug equivalents in
plasma, urine, and feces were determined. Plasma curves for both
groups of animals were statistically equivalent, as was urinary excretion
of drug equivalents. Fecal output in diphenoxylate-pretreated rats is
reduced; therefore, total excretion of drug equivalents in diphenoxylate-
pretreated animals is lower than in control animals after 48 hr.
The concentration of a given sedative drug in brain is
relatively constant upon waking, regardless of the duration of sleep.
Thus, we evaluated the effect of diphenoxylate on the concentration of
secobarbital and flurazepam equivalents in brain and blood. Total
radioactivity was measured in the blood and brain of control and
diphenoxylate-pretreated animals at various time periods following the
administration of C 14-secobarbital or C 4-flurazepam. The concentration
of drug equivalents in the blood and brain was essentially the same for
both control and diphenoxylate-pretreated animals with both drugs.
6
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Although sleeping times are approximately double in diphenoxylate
animals, the concentration of drug equivalents in both the brain and
blood of these animals at waking is less than that of controls. One
would have expected equivalent concentrations of secobarbital and
flurazepam if sedative drugs mediated the increase in sleeping times.
The increase in pharmacological activity when sedative drugs
are used in combination with diphenoxylate cannot be explained on the
basis of inhibition of drug metabolism. Studies in vitro performed
under our first NASA contract, in which microsomal hexobarbital oxidase
activity was measured in control and diphenoxylate-treated animals,
showed no difference between the two groups as defined by their Km
and Vmax values. Also, the physiological disposition studies just
completed found no pharmacokinetic differences of sedative drugs in
diphenoxylate-treated animals. Most likely, when sedative drugs are
administered, the diphenoxylate per se and/or metabolites which remain
in the brain for such long periods of time produce an additive effect
that is manifested in increased sleeping times.
7
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I. INTRODUCTION
The general approach to the use of drugs by astronauts during
space flights has been cautious, but in-flight medical problems requiring
their use have occurred. With the advent of the Sky Lab program, the
probability that astronauts may find it necessary to take one or more of
the drugs carried in their medical kits greatly increased. As has been
reviewed elsewhere (1), results of epidemiological studies of adverse
drug effects were of great consequence in bringing attention to drug
interactions. Of particular importance, a direct relationship between
the number of drugs used and the probability of adverse drug reactions
clearly emerged from these studies. Unquestionably, use of drugs in
combination carries with it an increased probability of an adverse drug
effect.
Adequate clinical data on risk/benefit ratios for particular
drugs are just now beginning to emerge. Similar data for drugs used in
combination are generally unavailable. The relative probabilities for
therapeutic mishap are highest for antimicrobials, cardiac drugs, and
hypnotics and sedatives. These classes are all heavily represented in
the list of drugs now contemplated for possible use during manned space
flight. With the Sky Lab program involving longer residence for astronauts
in space, this project was concerned with the increased possibility that
drugs would be taken in combination, with unknown effects.
P hG PAGE BLANI NOT .
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II. BACKGROUND
In our previous programs for NASA, we have studied the effect
of spacecraft environment on drug metabolism and on the pharmacological
activity of drugs. We have just finished a program designed to
investigate the potential interaction for various drug combinations.
Generally, we have concluded that most drugs under spacecraft environment
or in combination had no significant adverse effects. Diphenoxylate (I),
however, did appear to alter the pharmacodynamics of at least three
classes of drugs.
In our first NASA-sponsored studies, diphenoxylate potentiated
secobarbital and, to a lesser extent, hexobarbital-induced sleeping
times in rats. Diphenoxylate had been given 16-18 hr prior to the
barbiturates. Since barbiturate metabolism by liver microsomes in vitro
was unchanged in diphenoxylate-treated rats compared to control animals,
the potentiation does not appear to involve inhibition of barbiturate
metabolism by diphenoxylate.
In our second NASA program, we have recently shown that
diphenoxylate apparently increased the overall absorption of nitro-
furantoin, given either as the macrocrystalline dosage form or the
microcrystalline dosage form to dogs. In these studies, as before,
diphenoxylate was given to the dog 16-18 hr prior to the oral adminis-
tration of nitrofurantoin.
The striking feature of the drug interaction between diphenoxylate
and barbiturates in rats, and between diphenoxylate and nitrofurantoin
in dogs was the length of time between dosing the two drugs. Diphenoxylate
has been shown to be extensively metabolized in rats, dogs, and man (2,3).
In bile-cannulated rats, 90% of the administered label was recovered in
the bile (3). The major excretory pathway is the feces and the rate
of fecal excretion of the metabolites is slow. Thus, the extensive
11
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biliary secretion and slow fecal excretion is consistent with having an
enterohepatic cycle for diphenoxylate and its metabolites. A metabolite
of diphenoxylate, difenoxine, (II)(R15403), has been shown to be responsible
for the pharmacological activity associated with diphenoxylate (4-7) and
the pharmacokinetics of difenoxine in man and animals (4-7) are similar.
If diphenoxylate enters an enterohepatic cycle, then one would expect
a long biological half-life of the active component. Thus, any interaction
between diphenoxylate and a second drug many hours after the diphenoxylate
treatment could reasonably be expected.
The mechanism of interaction between diphenoxylate and nitro-
furantoin is probably due to the enhanced rate of absorption from the
G.I. tract. For example, nitrofurantoin is highly water insoluble and
the particle size is extremely important in its rate of solubilization
by the intestinal fluids. Since diphenoxylate decreases the G.I.
motility, the increased absorption of both the macro- and microcrystalline
nitrofurantoin probably is due to increased residence time of the drugs
in the G.I. tract.
The purpose of extending the present contract was to help
delineate the mechanism of interaction between diphenoxylate and certain
sedative drugs. Diphenoxylate is a meperidine congener that is used
exclusively in the treatment of diarrhea. Man in space takes diphenoxylate
as needed to control gastrointestinal motility. Other drugs, such as
sedatives and stimulants, may be used occasionally. The combination of
barbiturates and diphenoxylate has been used by United States astronauts
on prolonged space flights. The manufacturer's literature on diphenoxylate
states that the drug should be used with caution, if at all, in individuals
simultaneously receiving addicting drugs (tranquilizers, alcohol), or
barbiturates, because of potentiating effects (8). No data on interactions
between barbiturates and diphenoxylate appear in the open literature
and the manufacturer has informed us that no pharmacological work on
the combination has been done.
12
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We have thus proceeded to evaluate the effect of diphenoxylate
on the drug-induced sleeping time and pharmacodynamics of several
barbiturates, chloral hydrate, flurazepam, and meperidine.
DIPHENOXYLATE
0
II
N C-O-C2H5
C-CH2-CH2-N
I
DIFENOXINE
0
C-CH2-CH2-N
II
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III. MATERIALS AND METHODS
Pharmacological studies were set up to measure the effect of
diphenoxylate on sedative-induced sleeping times. Sleeping times were
recorded as the interval between loss and return of the righting reflex.
The criteria for measuring the loss and return of the reflex was the
inability and ability, respectively, of the animal to right itself within
30 sec when placed on its back (9).
Diphenoxylate at 10 mg/kg was given by intubation 16-18 hr
prior to administering the sedative drug intravenously. Control animals
received comparable doses of the vehicle (1% Tween 80/saline) at that
time. The dose for the sedative drug was based on the amount necessary
to produce a convenient, measurable sleeping time of 30-45 min in normal
rats.
Separate experiments were carried out using the following drugs:
pentobarbital, phenobarbital, secobarbital, hexobarbital, chloral hydrate,
and flurazepam. Ten control rats and ten diphenoxylate-pretreated rats
were used in each experiment. Means and standard deviations were cal-
culated for each group and the "t" test for significance run with the
results. Significance was defined as test results that differ from
control values by a "p" value of less than 0.05, as measured by the "t"
test. In other words, the probability (p) that the values obtained with
treated animals and values obtained with control animals are different
by chance alone is less than 5%.
An additional group of sleeping time experiments were run with
pentobarbital, secobarbital, chloral hydrate, and flurazepam, measuring
the effect of decreasing the dose of the sedative drug while all the
other factors were kept constant. Diphenoxylate at 10 mg/kg was again
administered by intubation 16-18 hr prior to the sedative drug while
control animals received 1% Tween 80/saline. The sedative drug was then
administered intravenously at the full dose and at one-half the original
15
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dose to groups of control and diphenoxylate-pretreated rats. Sleeping
times were measured and the results were analyzed statistically as
described above.
A final group of sleeping time experiments was run with
secobarbital and chloral hydrate. This time, the dose of the sedative
drug remained constant while the dose of diphenoxylate and the time
between the administration of diphenoxylate and the sedative drug were
varied. Diphenoxylate was given at doses of 0.16, 0.625, 2.5, and
10 mg/kg, and at 1, 8, 16, and 40 hr before dosing with the sedative
drug. Again, sleeping times and results were calculated as above.
Meperidine-induced analgesia was evaluated by use of the Eddy
hot plate technique (10). With a hot plate maintained at 580C, analgesic
activity was measured over a period of 2 hr, using a 20 sec cut-off time
(defined as 100% response). Percent analgesia was determined in control
and diphenoxylate-pretreated rats (20 animals/group) from the area under
the curve found by plotting the response time observed at various time
periods after the administration of meperidine.
Experiments were set up to measure the effect of diphenoxylate
on the plasma pharmacokinetics of the sedative drugs. Radioactive
drug was administered intravenously, at a dose level comparable to that
used in the pharmacological experiments, to both control and diphenoxylate-
pretreated rats (10 mg/kg p.o., 16-18 hr previously). Blood was obtained
from the optic vein at 1i, 2, 5, 10, 15, 30, 45, 60, 75, 90 min and
2, 3, 4, 6, 8, 12, and 24 hr. Radioactivity in plasma was determined
directly by liquid scintillation counting (11).
Urine and feces were collected from an additional group of
normal and diphenoxylate-pretreated rats dosed as above with radioactive
drug. Coprophagy was prevented by the tail-cup technique (12) and these
animals were housed in individual No. 110 metabolism cages (Maryland
Plastics, Inc., New York, N.Y.) for collection of urine and feces.
16
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Collection periods were 0-3, 3-6, 6-12, 12-24, and 24-48 hr after the
administration of the radioactive drugs. Radioactivity in urine was
determined directly by liquid scintillation counting, and in feces after
combustion by the Peterson technique (13).
The final group of experiments was designated to evaluate the
concentration of secobarbital and flurazepam equivalents in blood and
brain of control and diphenoxylate-pretreated rats. Diphenoxylate was
administered orally as before at 10 mg/kg, 16-18 hr prior to all
animals receiving C 4-secobarbital i.v. at 30 mg/kg or, in a separate
experiment, C 4-flurazepam i.v. at 60 mg/kg. Four control and four
diphenoxylate-pretreated rats were sacrificed at 2, 5, 10, 20, 45, 60,
90, and 120 min after administration of the radioactive drug. In addition,
6 control and 6 diphenoxylate-pretreated rats were sacrificed immediately
upon waking. Total equivalents were determined by direct counting of
the plasma and following combustion of the brain samples.
17
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IV. RESULTS AND DISCUSSION
A. PHARMACOLOGICAL STUDIES
1. Effect of Diphenoxylate on Sedative-Induced Sleeping Times.
Preliminary dose-ranging with the sedative drugs, using male, Sprague-
Dawley rats, established that the following doses produced sleeping times
of convenient length for control animals: pentobarbital, 20 mg/kg i.v.,
phenobarbital, 110 mg/kg i.v., secobarbital, 30 mg/kg i.v., hexobarbital,
80 mg/kg i.v., chloral hydrate, 200 mg/kg i.v., and flurazepam, 60 mg/kg i.v.
The selection of the initial dose of diphenoxylate was based on
the results of Janssen et al. (14). Janssen studied the influence of an
oral dose of diphenoxylate (R1132) on fecal excretion by Wistar rats by
quantitation of the number of fecal pellets passed over a period of 24
hr. At 10 mg/kg, significant effects were produced which persisted for
at least 48 hr after a single oral dose. At 1 mg/kg, a smaller but
measurable effect was seen on the first day following dosage but not on
the second day. Diphenoxylate was devoid of significant analgesic activity
in mice and rats following subcutaneous doses of up to 80 mg/kg of body
weight. To avoid the tedious and time comsuming task of dose-ranging
with diphenoxylate, we elected to use the initial oral dose of 10 mg/kg.
The effect of diphenoxylate on sleeping times with the "Skylab"
sedatives, secobarbital, chloral hydrate, and flurazepam and three
additional barbiturates are summarized in Table 1 and presented in
Tables 2-8. In all cases, the sleeping times for treated animals were
approximately twice those for control animals.
In an experiment reported to NASA (Contract NAS 9-9806) in
October 1970, chloral hydrate, administered i.p. at 200 mg/kg, showed
no potentiation of sleeping times in diphenoxylate-treated rats compared
to a control group. However, based on our present extensive work with
diphenoxylate and chloral hydrate (Tables 3 and 4), we will have to
Arthur D 19
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TABLE 1
SUMMARY: EFFECT OF DIPHENOXYLATE ON DRUG-INDUCED SLEEPING TIMES IN RATS
Sleeping Times - min
\Drug Dose (mg/kg i.v.) Control Diphenoxylate
Secobarbital 30 46 94
Chloral hydrate 200 36 74
Flurazepam 60 23 46
Pentobarbital 20 29 66
Phenobarbital 110 53 97
Hexobarbital 80 28 46
20
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TABLE 2
EFFECT OF DIPHENOXYLATE ON SECOBARBITAL-INDUCED a SLEEPING TIMES IN RATS
Control Sleep Diphenoxylate-dosedb
Times (min) Sleep Times (min)
41 91
39 105
41 65
34 93
47 73
54 110
52 119
56 98
Mean ± S.D. 45.5 + 7.9 94.3 + 18.2
"t" 6.96
p >0.01
a 30 mg/kg i.v.
b 10 mg/kg p.o., 17 hours prior to dosing with secobarbital
21
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TABLE 3
EFFECT OF DIPHENOXYLATE ON CHLORAL HYDRATE-INDUCEDa SLEEPING TIMES
IN RATS
Experiment 1
Control Sleep Times Diphenoxylate-dosedb Sleep Times
(min) (min)
40 69
37 67
39 71
41 77
30 71
40 71
38 83
24 81
28 76
37 72
35 73
37 74
35 78
32 73
40
37
36
38
Mean ±S.D. 35.78±4.6 Mean ±S.D. 74.00±4.5
"t" 23.54
p >0.01
a 200 mg/kg i.v.
10 mg/kg p.o., 17 hr prior to dosing with chloral hydrate
22
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TABLE 4
EFFECT OF DIPHENOXYLATE ON CHLORAL HYDRATE-INDUCEDa SLEEPING
TIMES IN RATS.
Experiment 2
Control Sleep Diphenoxylate-dosedb
Times (min) Sleep Times (min)
8 18
8 13
6 10
7 57
6 56
2 46
5 22
4 21
14 60
16 51
13 29
13 58
18 30
11 58
4 53
9 51
8 66
7 49
7 42
15 17
14 18
9 48
5 14
10 52
14 43
12
50
Mean ±S.D. 9.32±4.3 Mean ±S.D. 38.7+18.1
"t" 7.91
p >0.01
a 200 mg/kg i.p.
10 mg/kg p.o., 17 hr prior to dosing with chloral hydrate.
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TABLE 5
Effect of Diphenoxylate on Flurazepam-Induceda Sleeping Times in Rats
Control Sleep Times Diphenoxylate-dosedb Sleep
(min) Times (min)
25 54
26 46
16 49
32 56
30 49
25 39
19 40
21 34
18 . 41
23 56
23 37
11 54
24 39
Mean ±S.D. 22.54±5.6 45.69±7.8
"t" 8.69
p >0.01
a 60 mg/kg i.v.
10 mg/kg p.o., 17 hr prior to dosing with flurazepam.
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TABLE 6
EFFECT OF DIPHENOXYLATE ON PENTOBARBITAL-INDUCEDa SLEEPING TIMES IN RATS
Control Sleep Time (min) Diphenoxylate-dosed Sleep Timeb (min)
34 59
35 75
26 75
19 70
37 54
25 63
28 69
26
Mean ±S.D. 28.7 - 6.1 66.4 + 8.0
"t" 10.3
p >0.01
a 20 mg/kg i.v.
b 10 mg/kg p.o. 17 hr prior to dosing with pentobarbital.
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TABLE 7
EFFECT OF DIPHENOXYLATE ON PHENOBARBITAL-INDUCEDa SLEEPING TIMES IN RATS
Control sleep Diphenoxylate-dosed
times (min) sleep times (min)
56 91
54 99
56 100
58 98
52 102
39 94
62 94
52 95
48 101
94
Mean ± S.D. 53.0±6.6 96.8±3.7
"t" 18.10
p >0.01
a 110 mg/kg i.v.
10 mg/kg p.o., 17 hr prior to dosing with phenobarbital
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TABLE 8
EFFECT OF DIPHENOXYLATE ON HEXOBARBITAL-INDUCED SLEEPING TIMES IN RATS
Control Sleep Diphenoxylate-dosedb
Times (min) Sleep Times (min)
32 51
25 39
30 58
32 41
28 54
25 40
27 41
31 49
32 41
22 44
Mean+ S.D. 28.4 + 3.6 45.8 ± 6.7
"t" 7.23
p >0.01
a 80 mg/kg i.v.
b 10 mg/kg p.o., 17 hours prior to dosing with hexobarbital
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reverse the original conclusion and now state that there is a definite
potentiation effect when diphenoxylate and chloral hydrate are used
in combination.
Tables 9-13 demonstrate the effect of administering the sedative
drug at two dose levels, keeping the diphenoxylate dose constant at
10 mg/kg. As seen in summary Table 9, diphenoxylate increased the
sedative-induced sleeping times for four sedatives given at half the
dose. What is of note, however, is that diphenoxylate-dosed rats given
half the original dose of two barbiturates (Tables 10 and 11) and
chloral hydrate (Table 12) had sleeping times somewhat less than control
animals which received the full dose. Reducing the dose of flurazepam
to diphenoxylate-pretreated rats resulted in sleeping times generally
greater than control animals which received the full dose. Also sig-
nificant is the finding that the lower dose of sedative drug may not
produce a sleeping time, whereas the same dose to diphenoxylate-treated
animals always produces sedation- (Table 13).
2. Effect of Diphenoxylate on Meperidine-Induced Analgesia.
In our first NASA contract (NAS 9-9806) we studied the effect of
spacecraft environment on the metabolism of meperidine in vitro and on
meperidine-induced analgesia in the rat. We found that the 5 psia 100
percent oxygen environment was not sufficiently stressful to alter the
action of meperidine or its rate of biotransformation. This expertise
was used in the present study to investigate the interaction between
diphenoxylate and meperidine. The Eddy hot plate technique was used
to measure meperidine-induced analgesia and the control and diphenoxylate-
pretreated groups were compared in terms of "percent analgesia" observed
over a 2-hr test period. Percent analgesia is determined from the area
under a curve formed by plotting the response times observed at various
time periods.
The mean response times observed in control and diphenoxylate-
pretreated rats are shown in Figures 1 and 2. There were 20 animals per
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TABLE 9
SUMMARY: EFFECT OF DIPHENOXYLATE ON DECREASED DOSES OF SEDATIVE DRUGS
Sleeping Time - min
Drug Dose (mg/kg) Control Diphenoxylate
Secobarbital 30 46 78
15 15 36
Chloral hydrate 200 41 59
100 0 32
Flurazepam 60 21 43
30 8 32
Pentobarbital 20 38 55
10 5 22
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TABLE 10
EFFECT OF DIPHENOXYLATE ON SECOBARBITAL-INDUCED SLEEPING TIMES IN RATS
Secobarbital 30 mg/kg i.v. Secobarbital 15 mg/kg i.v.
Control Sleep Diphenoxylate-doseda  Control Sleep Diphenoxylate-doseda
Times (min) Sleep Times (min) Times (min) Sleep Times (min)
37 85 10 39
53 75 10 33
48 79 16 30
43 73 17 40
52 80 17 27
41 72 18 45
47 67 14 44
49 84 . 14 37
49 71 14 37
45 90 16 25
Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D.
46.4±4.97 77.6±7.2 14.6±2.8 35.7±6.8
"t" 11.3 "t" 9.1
p >0.01 p >0.01
a 10 mg/kg p.o., 17-18 hr prior to dosing with secobarbital
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TABLE 11
EFFECT OF DIPHENOXYLATE ON PENTOBARBITAL-INDUCED SLEEPING TIMES IN RATS
Pentobarbital 20 mg/kg i.v. Pentobarbital 10 mg/kg i.v.
Control Sleep Diphenoxylate-doseda  Control Sleep Diphenoxylate-doseda
Times (min) Sleep Times (min) Times (min) Sleep Times (min)
46 48 12 25
48 57 2 15
47 58 12 17
29 57 9 18
29 49 4 28
39 63 4 17
35 55 3 27
38 51 -b 27
32 67 -b 23
35 44 -b 25
Mean ±S.D. Mean ±S.D. Mean ±S.D. Mean ±S.D.
37.8±7.2 54.9±7.1 4.60±4.7 22.2±4.95
"t" 5.38 "t" 8.28
p >0.01 p >0.01
a 10 mg/kg p.o. 17-18 hr prior to dosing with pentobarbital
Animal did not lose righting reflex
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TABLE 12
EFFECT OF DIPHENOXYLATE ON CHLORAL HYDRATE-INDUCED SLEEPING TIME IN RATS
Chloral hydrate Chloral hydrate
200 mg/kg i.v. 100 mg/kg i.v.
Control Sleep Diphenoxylate-doseda  Control Sleep Diphenoxylate-dosed
a
Times (min.) Sleep Times (min.) Times (min.) Sleep Times (min.)
37 68 --b 24
37 78 -- 31
40 63 -- 31
-44 70 -- 31
38 45 -- 16
49 49 -- 36
38 59 -- 31
42 55 -- 42
41 -- 35
-- 44
Mean±SD 40.62±4.2 58.6±12.3 32.1±8.1
"t" 3.92
p>0 .01
a 10 mg/kg diphenoxylate, p.o. 16-18 hours prior to dosing with
flurazepam
b Animals did not lose righting reflex
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TABLE 13
EFFECT OF DIPHENOXYLATE ON FLURAZEPAM-INDUCED SLEEPING TIMES IN.RATS
Flurazepam 60 mg/kg i.v. Flurazepam 30 mg/kg i.v.
Control Sleep Diphenoxylate-doseda  Control Sleep Diphenoxylate-dosed
Time (min) Sleep Time (min) Time (min) Sleep Time (min)
26 41 24 30
22 45 - 27
21 46 6 18
25 39 -b 31
24 53 10 20
24 24 4 20
14 48 6 24
21 50 10 18
15 41 5 17
18 23 24 46
16 43 13 25
23 45 - 56
22 45 15 53
22 54 b 30
20 47 8 56
19 7 45
b
- 30
Mean ±S.D. 20.75±3.5 Mean ±S.D. 42.93±8.9 Mean ±S.D. 7.76±7.7 Mean ±S.D. 32.12±13.7
C7"t" 9.24 "t" 6.39
p >0.01 p >0.01
a 10 mg/kg p.o., 17-18 hr prior to dosing with flurazepam. Animal did not lose righting reflex.
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FIGURE 1
Meperidine-induced analgesic activity in control and diphenoxylate-
pretreated rats - Experiment 1.
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FIGURE 2
Meperidine-induced analgesic activity in control and diphenoxylate-
pretreated rats - Experiment 2.
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group in each experiment and the dose of meperidine was 30 mg/kg i.v.
The percent analgesia was significantly higher in diphenoxylate-pretreated
animals (57.5%) compared to control animals (33%)(Table 14).
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TABLE 14
MEPERIDINE-INDUCED ANALGESIA IN CONTROL AND DIPHENOXYLATE-PRETREATED
RATS
Time after Mean Reaction Time (sec.) ±S.D.
Injection Control Diphenoxylate-pretreatment
(min)
EXPERIMENT 1
0 6.4±2.6 10.5 ±3.7
20 17.6±3.3 19.2 ±2.4
40 13.4±4.8 17.4 +3.6
60 9.8±4.4 15.6 ±4.2
80 9.9±5.2 13.4 +4.4
100 8.1±3.7 11.5 ±5.3
120 6.6±2.7 11.7 ±5.6
Percent analgesia 33.0 56.5
EXPERIMENT 2
0 7.1±2.0 12.4 ±4.9
20 19.8±0.5 19.0 ±2.3
40 14.0±4.7 17.7 +3.2
60 10.6±4.5 14.9* 4.7
80 9.2±3.5 13.3 ±4.9
100 7.7±2.2 12.0 +4.7
120 7.4±1.9 10.8 ±4.4
Percent analgesia 32.8 58.5
* Significantly greater than control (p >0.05)
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B. MECHANISM OF INTERACTION BETWEEN DIPHENOXYLATE AND SEDATIVE
DRUGS.
Several possible mechanisms of action have been evaluated in
order to explain the enhanced sedation in diphenoxylate-pretreated
animals.
1. Drug Metabolism
The structural similarity of diphenoxylate to SKF-525A (III),
a known potent inhibitor of hepatic drug metabolism, initially prompted
the speculation that the potentiation of barbiturate action involved an
inhibition of microsomal enzymes. However, studies reported in the final
report for NASA contract NAS 9-9806 measuring microsomal hexobarbital
oxidase in control and diphenoxylate-pretreated animals showed no
difference in the two groups as defined by their Km and Vmax values.
0 CH 2CH 3
C - C C--OHCH2CH2N
(CH2 2 CH2CH3
CH3
SKF-525A III
2. Plasma and Excretion Pharmacokinetics of Sedative Drugs.
We evaluated the possibility that the enhanced sedation might relate
closely to the pharmacokinetics of the sedative drugs in the diphenoxylate-
pretreated rats. The barbiturates, pentobarbital, phenobarbital,
hexobarbital, and secobarbital and chloral hydrate were chosen because
they vary widely in their metabolism, excretion, and duration of
39
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pharmacological activity.
Radiolabeled sedative drugs were administered i.v. to both
control and diphenoxylate-pretreated rats. Drug equivalents in plasma,
urine, and feces were determined. The plasma pharmacokinetics of total
drug equivalents are presented in Tables 15-19 for all drugs, and
illustrated for secobarbital and chloral hydrate in Figure 3. Statistically,
the curves and data for all the barbiturates tested and for chloral
hydrate are equivalent to those obtained from control animals. Radio-
labeled flurazepam was not synthesized in time to be included in these
studies; however, a subsequent study on a smaller scale leads one to the
same conclusion.
Urinary excretion of drug equivalents was essentially the same
for both groups of animals, as can be seen in Tables 20-24, with the
possible exception of the chloral hydrate (Table 21). It appears that
urinary excretion of chloral hydrate equivalents is increased in
diphenoxylate-pretreated rats, although it must be pointed out that the
standard deviation values are high. Feces were analyzed from the
secobarbital, pentobarbital, and chloral hydrate experiments. The results
are presented in Tables 25-27. Fecal output of drug equivalents in the
diphenoxylate=pretreated rats is somewhat reduced and always delayed due
to the action of the drug.
3. Pharmacokinetics of Secobarbital and Flurazepam Equivalents
in Brain. In order to investigate further the pharmacodynamics of
sedative drugs in diphenoxylate-pretreated animals, we compared the
concentrations of secobarbital and flurazepam equivalents in blood and
brain of control and diphenoxylate-pretreated animals. Four control and
four diphenoxylate-pretreated rats were sacrificed at various time
periods up to 2 hr after receiving either C 4-secobarbital or C 4-flurazepam.
In addition, 6 control and 6 diphenoxylate-pretreated rats were
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TABLE 15
CONCENTRATION OF SECOBARBITAL EQUIVALENTS IN PLASMA OF CONTROL AND
DIPHENOXYLATE-PRETREATED RATSa
Time Controlb ,c Diphenoxylate-treatedb ,c
1 min 39.32 ± 3.99 55.58 ± 9.69
2 38.38 ± 3.76 48.58 ± 5.60
5 37.40 ± 2.84 44.66 ± 6.01
10 35.85 ± 1.85 42.24 ± 4.78
15 33.04 ± 5.81 38.74 ± 4.26
30 36.04 ± 2.46 41.78 ± 3.83
45 34.70 ± 1.94 40.70 ± 5.69
60 31.36 ± 3.35 41.40 ± 6.23
75 29.15 ± 2.00 35.40 ± 5.37
90 26.55 ± 4.15 32.50 ± 5.58
2 hr -d 27.90 ± 6.02
3 9.64 ± 2.62 13.94 ± 3.72
4 4.52 ± 1.47 -d
6 1.70 ± 0.66 3.28 ± 1.32
8 1.50- 0.45 2.50 ± 0.48
12 1.30 ± 0.12 1.52 ± 0.31
24 0.35 ± 0.10 0.42 ± 0.22
a Rats received either 10 mg/kg diphenoxylate or a comparable dose
of 1% Tween 80/saline p.o. 17 hr prior to dosing with 30 mg/kg
secobarbital i.v.
b Results expressed as mean pg/ml ±S.D. for 5 animals.
c The mean sleeping time ±S.D. for the control and diphenoxylate-
treated animals were:
45.5±7.9 and 94.3±18.2, respectively.
Sample lost.
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TABLE 16
LEVEL OF CHLORAL HYDRATE EQUIVALENTS IN PLASMA OF CONTROL AND DIPHENOXYLATE-
PRETREATED RATSa
Controlb,c + Chloral Hydrate Diphenoxylatebc + Chloral Hydrate
Rat No. 1 2 Mean±S.D. 6 7 Mean±S.D.
Time
1 min 189.78 227.14 208.5±26.4 234.83 275.48 255.2±28.7
2 212.88 203.46 208.2± 6.7 269.17 264.15 266.7± 3.5
5 249.77 240.82 245.3± 6.3 273.39 296.12 284.7±16.1
10 256.56 248.62 252.6± 5.6 291.30 317.97 304.6±18.8
15 247.90 270.15 259.0±15.7 282.66 257.43 270.1±17.8
30 259.90 298.10 278.9±27.0 299.94 280.77 290.4±13.6
45 233.49 291.12 262.3±40.7 284.91 285.55 285.2± 0.4
60 234.47 268.82 251.6±24.3 242.26 277.55 259.9±24.9
75 205.83 246.61 226.2±28.8 - d - d
90 185.84 175.34 180.6± 7.4 233.11 243.45 238.3± 7.3
2 hr 113.58 155.99 134.8±29.9 163.89 179.30 171.6±10.9
3 82.41 97.76 90.1±10.8 81.85 107.92 94.9±18.4
4 71.35 - d 77.72 89.86 83.8± 8.6
6 57.27 72.85 65.1±11.0 61.32 - d
8 71.38 56.73 64.1±10.4 90.01 66.52 78.3±16.6
12 48.20 50.16 49.2± 1.4 72.89 47.93 60.4±17.6
24 - d - d d d
48 13.62 11.40 12.5± 1.6 12.07 14.31 13.2± 1.6
a Rat received either 10 mg/kg diphenoxylate or a comparable dose of 1%
Tween 80/saline 17 hr prior to dosing with 200 mg/kg i.v. chloral hydrate.
b Results expressed as pg/ml.
The mean sleeping time±S.D. for control and diphenoxylate-treated rats
were: 35.2 ± 6.2 and 71.0 ± 3.7, respectively.
d Sample lost.
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TABLE 17
CONCENTRATION OF PENTOBARBITAL EQUIVALENTS IN PLASMA OF CONTROL AND
DIPHENOXYLATE-PRETREATED RATSa
Time Controlb c Diphenoxylate-treatedb,c
1 min 26.16 ± 6.44 25.12 ± 3.55
2 23.68 ± 4.94 21.51 ± 3.75
5 23.77 ± 3.25 21.64 ± 3.17
10 24.52 ± 5.71 21.32 ± 3.23
15 22.09 ± 0.85 21.20 ± 2.13
30 22.70 ± 2.13 21.68 ± 2.17
45 21.13 ± 1.25 20.10 ± 1.95
60 20.71 ± 1.65 19.13 ± 1.50
75 19.08 ± 2.12 18.37 ± 1.44
90 16.74 ± 1.75 15.82 ± 0.55
2 hr 12.86 + 1.99 13.54 ± 1.19
3 7.33 ± 1.48 9.74 ± 2.00
4 3.92 + 0.97 5.92 ± 1.54
6 1.13 ± 0.77 2.60 ± 0.65
8 0.96 ± 0.65 1.13 ± 0.67
12 0.50 ± 0.11 0.72 ± 0.60
24 0.30 ± 0.53 0.14 ± 0.11
48 0.04 ± 0.02 0.05 ± 0.02
a Rats received either 10 mg/kg p.o. diphenoxylate or a comparable dose of
1% Tween 80/saline 18 hr prior to dosing with 20 mg/kg pentobarbital i.v.
Results expressed as mean pg/ml ±S.D. for 5 rats
c The mean sleeping time ±S.D. for control and diphenoxylate-treated
rats were:
28.75 + 6.09 and 66.43 + 8.04
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TABLE 18
CONCENTRATION OF PHENOBARBITAL EQUIVALENTS IN PLASMA OF CONTROL AND
DIPHENOXYLATE-PRETREATED RATSa
Time Controlb 'c  Diphenoxylate-treated
1 min 276.89±67.72 296.50±44.99
2 252.38±75.99 258.52±20.18
5 239.82±24.49 221.42±16.36
10 234.24±21.96 226.00±42.49
15 235.36±25.94 216.72± 8.47
30 231.84±26.36 235.27±46.47
45 230.58±23.04 238.35±40.00
60 222.90±22.88 227.32±37.25
75 231.50±28.25 210.32±26.61
90 206.74±28.25 195.35±11.77
2 hr 211.82±38.87 189.15±18.30
3 214.96±53.29 168.95±11.28
4 187.76±23.45 161.50±11.79
6 170.30±36.78 142.62± 8.90
8 141.94±30.71 123.77±15.32
12 90.14±25.62 93.65± 9.93
24 32.78± 7.48 39.22± 5.37
48 2.10± 1.80 4.87± 1.97
a Rats received either 10 mg/kg p.o. diphenoxylate or a comparable dose of
1% Tween 80/saline 18 hr prior to dosing with 110 mg/kg phenobarbital i.v.
Results expressed as mean pg/ml ±S.D.
c The mean sleeping time ±S.D. for control and diphenoxylate-treated
rats were:
53.0±6.6 min and 96.8±3.7 min, respectively
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TABLE 19
CONCENTRATION OF HEXOBARBITAL EQUIVALENTS IN PLASMA OF CONTROL AND
DIPHENOXYLATE-PRETREATED RATSa
Time Controlb ,c Diphenoxylate-treated
b 
,c
1 min 101.06 ± 16.70 126.18 ± 19.38
2 106.22 ± 11.85 132.00 ± 14.47
5 125.68 ± 35.31 133.30 ± 10.57
10 129.00 ± 9.30 129.60 ± 12.81
15 129.44 ± 9.62 137.92 ± 10.98
30 135.96 ± 9.81 143.14 ± 9.67
45 137.14 ± 6.34 150.46 ± 7.58
60 134.86 ± 3.60 147.72 ± 6.57
75 126.20 ± 3.01 141.90 ± 2.41
90 117.00 ± 11.64 147.28 ± 9.13
2 hr 89.18 ± 3.21 116.60 ± 11.69
3 58.40 ± 21.32 75.56 ± 19.20
4 33.96 ± 12.13 51.72 ± 17.24
6 16.34 ± 4.79 24.54 ± 8.17
8 12.62 ± 1.26 17.12 ± 6.63
12 10.78-+ 1.16 11.54 ± 1.12
24 5.90 ± 0.32 6.30 ± 1.58
Rats received either 10 mg/kg diphenoxylate or a comparable dose
of 1% Tween 80/saline 17 hr prior to dosing with 80 mg/kg
hexobarbital i.v.
b Results expressed as mean vg/ml ± S.D. for 5 animals.
c The mean sleeping time ±S.D. for the control and diphenoxylate-
treated animals were:
28.4±3.6 and 45.8±6.7, respectively.
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FIGURE 3
Effect of Diphenoxylate on Plasma Pharmacokinetics of Secobarbital and
Chloral Hydrate Equivalents.
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TABLE 20
CONCENTRATION OF SECOBARBITAL EQUIVALENTS IN URINE OF CONTROL AND DIPHENOXYLATE-PRETREATED RATS
Time Control Diphenoxylate-treated
(hr) (Drug equivalents - mga) Mean ±S.D. (Drug equivalents - mga) an
Rat No. 1 2 3 4 5 6 7 8 9 10 11 12
0-6 0.18 2.06 1.47 1.88 2.42 1.60 1.60±0.77 1.87 2.27 0.85 1.67 2.39 2.05 1.85±0.56
6-9 0.39 0.45 0.21 0.25 0.10 2.19 0.60±0.79 0.36 0.01 0.81 0.23 0.77 0.25 0.41±0.32
9-12 0.12 0.13 0.05 0.11 0.10 0.13 0.11±0.03. 0.13 0.01 0.08 0.13 0.07 0.16 0.49±0.37
12-24 0.21 0.10 0.16 0.02 0.14 0.11 0.25+0.37 0.22 1.21 0.29 0.35 0.58 0.30 0.49±0.37
24-48 0.94 0.03 0.05 0.02 0.40 0.04 0.25±0.37 0.05 0.05 0.12 0.10 0.50 0.04 0.14±0.18
Total mg
excreted 1.83 2.79 1.94 2.28 3.16 4.07 2.68±0.85 2.64 3.56 2.16 2.47 4.31 2.81 2.99±0.80
in 48 hr
% of Dose 50.1 74.5 49.8 61.3 83.0 106.0 70.8 ±22.2 73.6 78.1 53.8 64.8 103.2 79.4 75.3 ±16.9
a Results expressed total mg excreted per collection period.
At
TABLE 21
CONCENTRATION OF CHLORAL HYDRATE EQUIVALENTS IN URINE OF CONTROL AND DIPHENOXYLATE-PRETREATED RATS
Time Control Diphenoxylate-treated
(hr) (Drug Equivalents - mg)a (Drug Equivalents - mg)a
Rat No. 1 2 3 4 5 6 Mean ±S.D. 7 8 9 10 11 Mean +S.D.
0-3 1.35 14.80 6.17 0.83 8.81 4.10 6.01 ±5.2 7.39 11.10 8.40 16.94 13.83 9.7 ± 5.6
3-6 2.20 1.30 3.97 2.15 0.20 3.28 2.18 ±1.3 0.62 4.04 9.71 4.43 8.31 6.8 ± 4.8
6-9 0.60 0.90 0.67 0.89 0.25 0.07 0.56 ±0.33 9.24 0.83 0.60 0.73 1.71 2.4 ± 3.4
9-12 0.32 0.17 0.33 0.27 0.34 1.64 0.51 ±0.56 1.04 0.01 0.32 0.34 0.36 0.40± 0.34
12-24 1.25 0.27 1.64 0.32 0.65 0.71 0.81 ±0.54 0.97 0.83 0.45 0.69 0.77 0.68± 0.23
24-48 0.49 0.21 0.10 0.25 0.36 0.48 0.32 ±0.16 0.15 0.45 0.22 0.66 0.57 0.38± 0.21
Total mg
excreted 6.21 17.65 12.88 4.71 10.61 10.28 10.4 ±4.7 19.41 17.26 19.75 23.79 25.55 20.5 ± 3.4
in 48 hr
% of Dose 25 74 52 19 41 40 41.8 ±19.7 71 64 74 89 97 76.3 ±13.8
a Results expressed as total mg excreted per collection period.
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TABLE 22
CONCENTRATION OF PENTOBARBITAL EQUIVALENTS IN URINE OF CONTROL AND DIPHENOXYLATE-PRETREATED RATS
Time Control Diphenoxylate-treated
(hr) (Drug Equivalents - mga) (Drug Equivalents - mga)
Rat No. 1 2 3 4 5 Mean iS.D. 6 7 8 9 10 Mean +S.D.
0-6 1.53 1.79 0.90 1.52 1.19 1.39 ± 0.35. 1.11 1.64 0.49 0.54 1.21 0.99 ± 0.48
6-9 0.11 0.10 0.17 0.16 0.10 0.13 ± 0.03 0.04 0.01 0.27 0.10 0.30 0.16 ± 0.16
9-12 0.03 0.09 0.08 0.04 0.16 0.08 ± 0.06 b 0.16 0.20 0.11 0.16 0.16 ± 0.04
12-24 0.06 0.05 0.21 0.21 0.06 0.12 + 0.08 0.35 0.11 0.30 0.27 0.19 0.24 ± 0.09
24-48 0.01 0.01 0.03 0.01 0.03 0.02 + 0.01 0.04 0.06 0.09 0.05 0.02 0.05 ± 0.02
Total mg
excreted 1.74 2.04 1.39 1.94 1.55 1.73 + 0.27 1.55 1.98 1.35 1.07 1.98 1.59 ± 0.40
in 48 hr
% of Dose 70.4 82.2 60.0 78.3 61.1 70.4 + 9.9 57.0 72.3 44.7 44.3 72.3 58.1 ±13.9
a Results expressed as total mg excreted per collection period
No urine excreted
TABLE 23
CONCENTRATION OF PHENOBARBITAL EQUIVALENTS IN URINE OF CONTROL AND DIPHENOXYLATE-PRETREATED RATS
Time Control Diphenoxylate-treated
(hr) (Drug Equivalents-mga) (Drug Equivalents-mga)
Rat No. 1 2 3 4 5 6 Mean +S.D. 7 8 9 10 11 12 Mean ±S.D.
0-6 5.49 1.62 2.33 2.55 3.92 2.00 2.98±1.45 2.10 1.10 0.0 0.0 0.71 0.0 0.65±0.84
6-9 0.02 0.25 0.65 0.47 1.38 0.17 0.49±0.48 0.12 0.06 2.26 4.22 0.03 1.98 1.44±1.69
0 9-12 0.66 0.34 1.15 0.88 0.48 0.52 0.67±0.29 0.60 1.03 0.23 1.58 0.87 0.89 0.87±0.45
12-24 3.35 1.85 2.35 2.58 2.00 2.64 2.46±0.53 2.12 2.38 5.10 3.29 3.63 3.39 3.32+1.06
24-48 1.61 0.92 1.05 1.10 0.81 1.63 1.19±0.35 0.16 2.44 2.11 1.79 0.46 2.43 1.56±1.00
Total mg
excreted 11.03 4.98 7.53 7.58 8.59 6.96 7.73±1.99 5.10 7.01 9.70 10.88 5.70 8.69 7.85±2.28
in 48 hr
% of 75.5 42.2 59.2 62.6 64.1 52.7 59.7±11.2 37.1 48.7 59.9 75.0 39.3 59.9 53.3±14.4
Dose
a Results expressed as total mg excreted per collection period
5-
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TABLE 24
CONCENTRATION OF HEXOBARBITAL EQUIVALENTS IN URINE OF CONTROL AND DIPHENOXYLATE-PRETREATED RATS
Time Control Diphenoxylate-treated
(hr) (Drug equivalents - mga) (Drug equivalents - mga)
Rat No. 1 2 3 4 5 6 Mean ±S.D. 7 8 9 10 Mean ±S.D.
0-6 9.44 8.64 10.62 11.21 9.90 7.80 9.60±1.26 6.33 7.60 8.31 8.62 7.72±1.02
6-9 2.15 1.36 0.99 0.82 1.85 0.47 1.27±0.64 3.34 -b 3.02 1.10 2.49±1.21
9-12 0.14 0.57 0.56 0.33 1.10 2.35 0.84±0.81 2.32 -b 1.10 1.42 1.61±0.63
- 12-24 1.87 0.71 0.72 0.32 1.04 1.17 0.97±0.53 1.05 7.80 1.90 1.47 1.47±0.43
24-48 0.26 0.28 0.20 0.13 0.24 0.35 0.97±0.53 0.52 0.21 0.11 0.17 1.47±0.43
Total mg
excreted 13.86 11.56 13.09 12.79 14.14 12.14 12.93±0.99 13.56 15.61 14.44 12.78 14.10±1.22
in 48 hr
% of 122.3 117.8 123.5 130.5 125.3 114.6 123.8 ±4.4 120.9 137.1 125.7 118.2 126 ±9.2
Dose
a Results expressed as total mg excreted per collection period
b
No urine excreted
CD
TABLE 25
CONCENTRATION OF SECOBARBITAL EQUIVALENTS IN FECES OF CONTROL AND DIPHENOXYLATE-PRETREATED RATS
Time Control Diphenoxylate-treated
(hr) (Drug Equivalents - mga) (Drug Equivalents - mg a)
Rat No. 1 2 3 4 5 6 Mean ±S.D. 7 8 9 10 11 12 Mean ±S.D
0-6 0.24 0.26 0.01 0.03 0.01 - 0.11±0.13 0.01 0.08 0.01 0.001 0.01 0.01 0.02±0.02
6-9 0.29 0.33 0.44 0.26 0.66 0.37 0.39±0.14 0.03 0.15 0.01 0.03 0.03 0.01 0.04±0.05
9-12 0.11 0.20 0.19 0.21 0.21 0.32 0.21±0.07 0.33 0.09 0.002 0.48 0.03 0.03 0.16±0.19
12-24 0.18 0.10 0.16 0.17 0.11 0.19 0.15±0.04 0.23 0.32 0.18 0.13 0.33 0.22 0.23±0.08
24-48 0.05 0.01 0.04 0.03 0.07 0.04 0.04±0.02 0.07 0.07 0.16 0.12 0.05 0.06 0.09±0.04
Total mg
excreted 0.87 0.90 0.84 0.70 1.06 0.92 0.88±0.12 0.67 0.71 0.36 0.76 0.45 0.33 0.55±0.19
in 48 hr
% of Dose 24 24 22 19 28 24 23.5 ±2.9 18 16 9 20 11 10 14.0 ±4.6
a Results expressed as total mg per collection period.
TABLE 26
CONCENTRATION OF CHLORAL HYDRATE EQUIVALENTS IN FECES OF CONTROL AND DIPHENOXYLATE-PRETREATED RATS
Time Control Diphenoxylate-treated
(hr) (Drug Equivalents - mga) (Drug Equivalents - mga)
Rat No. 1 2 3 4 5 6 Mean +S.D. 7 8 9 10 11 Mean 
+ S.D.
0-3 0.04 0.002 -b 0.02 -b 0.003 0.02±0.02 _b 0.002 0.004 0.002 0.005 0.003±.001
3-6 0.05 0.02 0.07 0.03 0.003 0.004 0.03±0.03 0.07 0.02 0.02 0.02 0.008 0.03 ±.02
6-9 0.01 0.16 0.03 0.02 0.02 0.06 0.05±0.06 0.02 0.04 0.03 0.007 0.02 0.02 ±.01
9-12 0.02 0.002 0.02 0.03 0.04 0.04 0.03±0.01 0.09 0.03 0.01 0.04 0.006 0.03 ±.03
12-24 0.07 0.06 0.05 0.07 0.06 0.05 0.06±0.001 0.08 0.07 0.09 0.08 0.05 0.07 ±.01
24-48 0.05 0.06 0.04 0.12 0.07 0.02 0.06±0.03 0.08 0.09 0.12 0.05 0.06 0.08 ±.03
Total mg
excreted 0.24 .30 0.21 0.28 0.19 0.17 0.23±0.05 0.34 0.25 0.27 0.19 0.15 0.24 ±.07
in 48 hr
% of
Dose 1.0 1.3 0.9 1.2 0.8 0.7 0.98±0.23 1.3 1.0 1.0 0.7 0.6 0.92 ±.3
a Results expressed as mg per collection period.
No feces collected
-t
TABLE 27
CONCENTRATION OF PENTOBARBITAL EQUIVALENTS IN FECES OF CONTROL AND DIPHENOXYLATE-PRETREATED RATS
Time Control Diphenoxylate-treated
(hr) (Drug Equivalents - mga) (Drug Equivalents - mga)
Rat No. 1 2 3 4 5 Mean ±S.D. 6 7 8 9 10 Means ±S.D.
0-6 0.179 0.004 -b 0.0003 -b 0.037±0.080 0.003 0.004 0.002 0.004 0.004 0.003±0.001
6-9 0.175 0.234 0.195 0.024 0.188 0.163±0.081 0.002 0.005 0.001 0.001 0.009 0.004±0.003
9-12 0.061 0.085 0.111 0.195 0.179 0.i26±0.059 0.004 0.078 b 0.006 0.026 0.023±0.003
12-24 0.064 0.081 0.108 0.130 0.088 0.094±0.026 0.099 0.227 0.162 0.140 0.123 0.150±0.049
24-48 0.009 0.012 0.094 0.044 0.034 0.039±0.034 0.036 0.031 0.024 0.046 0.025 0.032±0.009
Total
mg ex- 0.488 0.416 0.508 0.444 0.489 0.469±0.038 0.144 0.345 0.189 0.197 0.187 0.212±0.077
creted
in 480
% Dose 19.6 16.8 20.9 17.5 19.3 18.8 ±1.7 5.3 12.6 6.2 8.2 6.8 7.8 ±2.9
a Results expressed as total mg per collection period
No feces excreted
>
sacrificed immediately upon waking. Figures 4 and 5 show that the
concentration of drug equivalents in the blood and the brain is essentially
the same for both groups of animals. In the secobarbital experiment,.
the control animals slept for an average of 58 min, while the diphenoxylate-
pretreated rats averaged 109 min. Although the sleeping times are
approximately double in diphenoxylate animals, the concentration of
secobarbital equivalents at waking is less in both the brain and blood
of the diphenoxylate-treated animals compared to control animals. The
same is true for the level of flurazepam equivalents in control animals
which slept for 17 min and treated rats which slept for 55 min. One
would have expected equivalent concentrations of sedative drug equivalents
if the sedative drug itself had mediated this increased sleeping time.
4. Effect of Dose and Time of Administration of Diphenoxylate
on Sedative-Induced Sleeping Times.
Janssen and associates in Belgium have shown that diphenoxylate
and its metabolites distribute into the brain of rats and remain there
for long periods of time (Table 28). Thus, we evaluated the effect of
varying the dose and the time of administration of diphenoxylate in
combination with secobarbital and chloral hydrate. Rats were dosed
orally with diphenoxylate at four concentrations, and the sedative drugs
were administered at four time periods thereafter (Tables 30-33). As
the concentration of diphenoxylate increased, the length of sleeping times
with secobarbital increased significantly (Table 29). When secobarbital
was administered 1 hr after the animals received 0.16 mg/kg diphenoxylate,
there was no significant increase in sleeping times. However, when the
secobarbital was administered 40 hr following the 0.16 mg/kg dose
of diphenoxylate, sleeping times were increased. A similar increase
can be seen with the 0.625 and 2.5 mg/kg doses of diphenoxylate. Thus,
as the length of time between dosing with diphenoxylate and dosing with
secobarbital increased, the length of sleeping times are significantly
increased. This is not the case at the 10 mg/kg concentration of
diphenoxylate, as the increase in sleeping times of treated animals
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FIGURE 4
Effect of diphenoxylate on the pharmacokinetics of secobarbital equivalents
in plasma and brain.
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FIGURE 5
Effect of diphenoxylate on the pharmacokinetics of flurazepam equivalents
in plasma and brain.
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TABLE 28
CONCENTRATION OF DIPHENOXYLATE (R1132) AND DIFENOXINE (R15403) IN BRAIN AND BLOOD OF RATS*
Dose of
Diphenoxylate 0.16 0.63 2.5 10
(mg/kg)
Time Total H3  Total H3  Total H3  Total H3
(Hr) Equiv. R1132 R15403 Equiv. R1132 R15403 Equiv. R1132 R15403 Equiv. R1132 R15403
Brain (nanograms)
1 17 5 41 13 99 31 241 76
2 16 3 4 41 7 9 106 19 21 270 50 48
16 11 0 2 36 2 8 114 6 27 357 20 91
0 32 9 0 1 32 1 7 110 5 27 383 19 102
64 6 0 1 25 1 5 101 4 22 407 18 93
Blood (nanograms)
1 1167 459 2633 1036 5970 2349 13597 5351
2 684 177 208 1667 433 459 4086 1061 1016 10066 2615 2259
16 156 5 121 494 17 374 1577 54 1160 5061 174 3621
32 92 1 50 326 6 203 1155 24 826 4117 87 3390
64 56 0 11 223 2 64 887 11 372 3551 44 2177
* J.J.P. Heykants, P.J. Lewi, and P.A.J. Janssen. Difenoxine (R15403), The Active Metabolite of
Diphenoxylate (R1132). Part 4: Distribution in the Rat of Diphenoxylate and Difenoxine. Arzneim-
Forsch (Drug Res.) 22:520, 1972.
C-
TABLE 29
SUMMARY: TIME AND DOSE EFFECTS OF DIPHENOXYLATE ON DRUG-INDUCED
SLEEPING TIMES
DIPHENOXYLATE (mg/kg) 0.16 0.625 2.5 10
PERCENT OF CONTROL SLEEPING TIME
PRETREATMENT (HOURS) SECOBARBITAL
1 116 133* 156* 203*
16 149* 177* 209*
40 133* 157* 210*
CHLORAL HYDRATE
1 105 113 191*
16 171*
40 107 92 131*
Significantly greater than control. Based on original data.
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TABLE 30
EFFECT OF DIPHENOXYLATEa ON SECOBARBITAL-INDUCEDb SLEEPING TIMES IN RATS - EXPERIMENT 1
Time of dosing with diphenoxylate
prior to receiving secobarbital 40 hr 8 hr 1 hr Controlc
57 65 55 23
60 61 60 24
56 51 63 37
68 56 40 36
71 66 55 25
54 62 60 32
67 66 66 28
63 58 59 29
o 51 66 26
62 68 31
Mean ±S.D. 60.9 ± 6.5 61.9 ± 5.4 57.3 ± 7.9 29.1 ± 4.9
"t" value plus t = 12.354 t = 14.225 t = 9.306
probability factor p<0.01 p<0.01 p<0.01
a Dose of diphenoxylate was 10 mg/kg p.o.
Dose of secobarbital was 30 mg/kg i.v.
c Control animals received secobarbital only.
C"
TABLE 31
EFFECT OF DIPHENOXYLATE ON SECOBARBITAL-INDUCEDa SLEEPING TIMES IN RATS - EXPERIMENT 2
Time 1 hr prior to receiving secobarbital 16-18 hr prior to receiving secobarbital
Dose of b
Diphenoxylate 10 mg/kg 2.5 mg/kg 0.625 mg/kg Controlsb 10 mg/kg 2.5 mg/kg 0.625 mg/kg Controls
(p.o.)
86 75 64 43 98 100 71 60
87 63 64 44 122 121 64 64
97 77 46 40 95 95 92 57
93 49 67 43 105 98 70 53
88 66 64 37 102 110 61 43
91 58 64 37 102 95 97 54
89 75 64 41 92 87 109 50
86 67 42 44 89 87 98 52
88 67 40 48 87 107 92 54
70 51 91 69 56 56
Mean ±S.D. 89.4±3.6 66.7±8.5 57.2±11.1 42.8±4.4 98.3±10.3. 96.9±14.3 81.0±18.6 54.3±5.6
"t" value t=25.084 t=7.896 t=3.794 t=11.868 t=8.772 t=4.347
plus
probability p<0.01 p<0.00.01 p<O.01 p<0.01 p<0.01 p<0.01
factor
a Dose of secobarbital was 30 mg/kg i.v.
b Control animals received 1% Tween 80/saline (diphenoxylate vehicle) at 0.5 ml/100 g rat either 1 hr
or 16-18 hr prior to receiving secobarbital.
4-,
4-,
TABLE 32
EFFECT OF DIPHENOXYLATE ON SECOBARBITAL-INDUCEDa SLEEPING TIMES IN RATS - EXPERIMENT 3
Time prior to receiving
Secobarbital 40 hr 8 hr 1 hr
Dose of
Diphenoxylate 2.5 mg/kg 0.625 mg/kg 0.16 mg/kg 0.16.mg/kg 2.5 mg/kg 0.625 mg/kg 0.16 mg/kg Controlb
(p.o.)
52 67 53 42 57 52 51 41
50 79 47 39 61 58 50 35
51 67 57 50 60 41 37 37
46 61 53 35 56 52 46 34
50 61 41 48 66 57 36 35
43 57 60 34 55 46 48 41
60 55 56 34 60 49 54 45
43 57 56 43 70 36 49 39
52 56 43 43 70 60 32 36
47 53 35 56 50 43
Mean ±S.D. 49.4±5.0 61.3±7.8 51.8±6.6 40.3±5.8 61.6±5.7 50.7±7.8 45.3±7.5 39.1±4.4
I"t" value t=4.890 t=7.839 t=4.985 t=0.521 t=9.690 t=4.096 t=2.255
plus
probability p<0.01 p<0.01 p<0.01 p<0.7 p<0.01 p<0.01 p<0.02factor
a Dose of secobarbital was 30 mg/kg i.v.
bb Control animals received 1% Tween 80/saline (diphenoxylate vehicle) at 0.5 ml/100 g rat 1 hr prior to
receiving secobarbital.
0:
TABLE 33
EFFECT OF DIPHENOXYLATE ON CHLORAL HYDRATEa-INDUCED SLEEPING TIMES IN RATS
Time prior to receiving
Chloral Hydrate 40 hr 8 hr 1 hr
Dose of
Diphenoxylate 10 mg/kg 0.625 mg/kg 0.16 mg/kg 0.16 mg/kg 10 mg/kg 0.625 mg/kg 0.16 mg/kg Controlb
(p.o.)
55 37 44 39 78 43 30 31
38 34 30 39 71 49 37 35
53 36 47 40 60 32 40 42
43 40 46 31 73 45 40 40
50 40 40 37 63 45 39 43
39 30 44 37 76 29 40 36
54 42 41 34 76 59 35 39
51 33 30 40 75 29 40 31
40 44 35 56 45 34
23 36 70 35
Mean ±S.D. 47.8±6.8 33.5±7.3 40.2±3.1 36.9±3.1 69.8±7.6 41.4±10.6 38.4±4.2 36.6±4.2
"t" value t=4.300 t=1.164 t=1.520 t=0.175 t=12.091 t=1.317 t=0.933
plus
probability p<0.01 p<0.2 p=0.2 p<0.9 p<0.01 p<0.3 p<0.4
factor
a Dose of chloral hydrate was 200 mg/kg i.v.
b Control animals received 1% Tween 80/saline (diphenoxylate vehicle) at 0.5 ml/100 g rat 8 hr prior to
receiving chloral hydrate.
over control animals appears to peak at approximately 200%.
With chloral hydrate as the sedative drug, the only significant
increase in sleeping times occurred with the highest dose of diphenoxylate.
Also, as the time between dosing with diphenoxylate and dosing with this
high dose of chloral hydrate increased, the sleeping times, though still
significant when compared with controls,decreased (Table 29). This
may relate to the reported decrease in the parent drug in the brain
during the pretreatment period. In addition, the absence of any
enhanced sleeping time at the lower doses of diphenoxylate with chloral
hydrate may be explained by the low concentration of diphenoxylate and
its short duration in the brain.
Taking into account Janssen's observations concerning the
pharmacokinetics of diphenoxylate, which show that the concentration of
diphenoxylate decreases with time but the concentration of metabolites
of diphenoxylate increases with time, one could suggest that the inter-
action between diphenoxylate and secobarbital may be associated with
metabolites of diphenoxylate, whereas with chloral hydrate, it may be
the diphenoxylate per se. The degree of depression, or action of the
sedative drugs, depends not only on the particular drug, the dose, and
the rate of administration, but also on the degree of excitability of
the CNS at the time of administration and the extent to which previous
experience with drugs has induced tolerance (15).
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V. CONCLUSION
The increase in pharmacological activity when sedative drugs
are used in combination with diphenoxylate cannot be explained on the
basis of inhibition of drug metabolism or pharmacokinetic differences
of the sedative drugs in diphenoxylate-pretreated animals. More than
likely, it is the diphenoxylate per se and/or metabolites that remain
in the brain for such long periods of time that when sedative drugs are
administered, an additive effect can be seen as manifested in increased
sleeping times or a higher level of meperidine analgesia.
Diphenoxylate is the drug of choice in many instances for the
control of diarrhea. Since the work reported in this contract has shown
that diphenoxylate can affect the pharmacodynamics of three classes of
drugs - sedative drugs, analgesics, and urinary antiseptics - caution
should be advised in administering drugs, especially CNS-acting drugs,
to diphenoxylate-treated subjects.
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